ライフサイエンスコーパス: sPLA2-IIA

1 sPLA2-IIA also bound to alpha4beta1.

2 Secreted group IIA-phospholipase A2 (sPLA2-IIA) from the Pla2g2a gene can bind to gram-positi

3 The type IIA secretory phospholipase A2 (sPLA2-IIA) is a host protein endowed with antibacterial

4 f human group IIA secreted phospholipase A2 (sPLA2-IIA), a bactericidal enzyme induced during acute i

5 Group IIA secretory phospholipase A2 (sPLA2-IIA), released during inflammation, is increased i

6 Independent of its catalytic activity, sPLA2-IIA induces pro-inflammatory signals in a receptor

7 ment significantly attenuated PLA2 activity, sPLA2-IIA mRNA and protein levels, and PtdCho-PLC activi

8 s Ptd-Cho levels by differentially affecting sPLA2-IIA, PtdCho-PLC, and CCTalpha after transient foca

9 individuals, indicating that GBS induces an sPLA2-IIA response in blood during human infection.

10 ) levels yet lower oxLDL/LDL (P = 0.006) and sPLA2-IIA mass (P = 0.04), probably reflecting LD with P

11 sine-mediated inhibition of phagocytosis and sPLA2-IIA expression.

12 ggest that both secretory PLA2 (sPLA2)-V and sPLA2-IIA (encoded, respectively, by the neighbouring PL

13 Because sPLA2-IIA is induced during inflammation, and 12-LO expr

14 o determine whether the relationship between sPLA2-IIA and coronary heart disease is causal.

15 isolates are highly sensitive to killing by sPLA2-IIA but not by human antimicrobial peptides.

16 hydrolysis of the mitochondrial membrane by sPLA2-IIA yields inflammatory mediators (ie, lysophospho

17 6 C allele associated with lower circulating sPLA2-IIA mass (38% to 44%) and sPLA2 enzyme activity (3

18 enzyme activity in inbred strains containing sPLA2-IIA mutations; these strains were also associated

19 ggest that, in the airway, S. aureus escapes sPLA2-IIA-mediated killing through adenosine-mediated in

20 3 and alpha4beta1 may serve as receptors for sPLA2-IIA and mediate pro-inflammatory action of sPLA2-I

21 but catalytic activity is not required, for sPLA2-IIA-induced proliferative signaling.

22 Using transgenic mice that express human sPLA2-IIA, we demonstrate that this enzyme is crucial fo

23 egulation of secretory phospholipase A2 IIA (sPLA2 IIA) mRNA and protein expression, increased PLA2 a

24 and increased secretory phospholipase 2-IIA (sPLA2-IIA) levels.

25 substrate of secreted phospholipase A2 IIA (sPLA2-IIA), a phospholipase otherwise specific for bacte

26 d activity of secreted phospholipase A2 IIA (sPLA2-IIA), present in inflammatory fluids, and platelet

27 rkers, secretory phospholipase A2 group IIA (sPLA2-IIA) and compares with other biomarkers on their p

28 Secretory phospholipase A2 group IIA (sPLA2-IIA) has been identified as a biomarker of atheros

29 Secretory phospholipase A2 group IIA (sPLA2-IIA) plays an important role in the pathogenesis o

30 However, the role of adenosine in sPLA2-IIA-mediated S. aureus killing by host is still un

31 We identified amino acid residues in sPLA2-IIA (Arg-74 and Arg-100) that are critical for int

32 adenosine production (adsA strain) increased sPLA2-IIA expression in guinea pig airways and was clear

33 S. aureus adsA strain induced sPLA2-IIA expression by alveolar macrophages after phago

34 atory action of sPLA2-IIA, and that integrin-sPLA2-IIA interaction is a novel therapeutic target.

35 previously associated with higher and lower sPLA2-IIA levels respectively.

36 able analysis for MVE for a 1-log unit lower sPLA2-IIA mass was 1.04 (95% CI: 0.96 to 1.13), and diff

37 mice, we show that the coordinated action of sPLA2-IIA and 12-LO promotes inflammatory arthritis.

38 2-IIA and mediate pro-inflammatory action of sPLA2-IIA, and that integrin-sPLA2-IIA interaction is a

39 ought to represent the composite activity of sPLA2-IIA, -V, and -X.

40 veolar macrophages, leading to inhibition of sPLA2-IIA expression.

41 n a previous study, a selective inhibitor of sPLA2-IIA (LY315920NA/S-5920) was well tolerated and app

42 c peptide, and a small molecule inhibitor of sPLA2-IIA ameliorated drusen accumulation in AMD/MD iPSC

43 Continuous 7-day infusion of an inhibitor of sPLA2-IIA had no beneficial effect on 28-day all-cause m

44 sive GBS disease contain increased levels of sPLA2-IIA compared with normal sera from healthy individ

45 Higher circulating levels of sPLA2-IIA mass or sPLA2 enzyme activity have been associ

46 l in ED and was analysed for serum levels of sPLA2-IIA, high-sensitive C-reactive protein (CRP), proc

47 nd the catalytically inactive H47Q mutant of sPLA2-IIA induced cell proliferation and ERK1/2 activati

48 The performance of sPLA2-IIA (AUROC 0.93 [95% CI: 0.89-0.97]; Sn 80% [95% C

49 found in neutrophils only in the presence of sPLA2-IIA and 12-LO in an in vivo model of autoimmune in

50 Elevated plasma sPLA2-IIA predicts coronary heart disease (CHD) risk, bu

51 defines a causal role of the MMP2-DAMP-RAGE-sPLA2-IIA axis in AMD/MDs.

52 Reducing sPLA2-IIA mass is unlikely to be a useful therapeutic go

53 uggests that cytokine induction up-regulates sPLA2 IIA protein expression, resulting in altered lipid

54 er, the M-type receptor is species-specific: sPLA2-IIA binds to the M-type receptor in rodents and ra

55 This finding suggested sPLA2-IIA was recommended biomarkers for BI detection in

56 Here we demonstrated that sPLA2-IIA bound to integrin alphavbeta3 at a high affini

57 vide experimental and clinical evidence that sPLA2-IIA protects humans against GBS infections.

58 We showed that sPLA2-IIA competed with VCAM-1 for binding to alpha4beta

59 t is entirely due to sPLA2-IIA, showing that sPLA2-IIA might represent an important component of humo

60 The sPLA2-IIA was also found superior to N%, PCT, and lactat

61 s11573156, a variant in PLA2G2A encoding the sPLA2-IIA isoenzyme, as an instrumental variable.

62 Consistent with predictions from the sPLA2-IIA gene sequence in inbred strains, we detected l

63 Thus sPLA2-IIA receptors in human have not been established.

64 t the bactericidal effect is entirely due to sPLA2-IIA, showing that sPLA2-IIA might represent an imp

65 own by sequencing to carry variant wild-type sPLA2-IIA alleles.

66 significantly attenuated infarction volume, sPLA2 IIA protein expression, PLA2 activity and signific

67 ypes of PLA2G2A are strongly associated with sPLA2-IIA mass, but not lipid levels.

68 s of intestinal tissues were consistent with sPLA2-IIA activity levels.